Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Idexx Laboratories (IDXX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IDXX broke through the 20-day moving average, which suggests a short-term bullish trend.
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.